Welcome to our dedicated page for SBPH news (Ticker: SBPH), a resource for investors and traders seeking the latest updates and insights on SBPH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SBPH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SBPH's position in the market.
F-star Therapeutics has completed its business combination with Spring Bank Pharmaceuticals, following stockholder approval on November 19, 2020. The merger leads to a new ownership structure where F-star shareholders hold 53.7% of the combined company. A $15 million investment from a syndicate of investors boosts F-star's cash reserves to approximately $30 million post-transaction. The combined entity will trade on Nasdaq under the ticker 'FSTX' starting November 23, 2020. Eliot Forster continues as CEO, emphasizing a commitment to innovative cancer therapies.
Spring Bank Pharmaceuticals (Nasdaq: SBPH) announced the approval of a 1-for-4 Reverse Stock Split, effective November 20, 2020. This decision follows a special stockholder meeting where stockholders also approved an exchange of shares with F-star Therapeutics Limited. The reverse stock split will reduce the outstanding shares, with four pre-split shares combining into one new share, and no fractional shares will be issued. Additionally, upon completion of the exchange, the company's name will change to F-star Therapeutics, Inc.
Spring Bank Pharmaceuticals (Nasdaq: SBPH) plans a one-time special dividend, subject to stockholder approval and a reverse stock split. This dividend will provide contractual rights to receive contingent value rights (CVRs) associated with Spring Bank's proprietary STING compounds, SB 11285 and its antagonist. The record date for this dividend is November 19, 2020, with payment expected prior to a proposed merger with F-star Therapeutics on November 20, 2020. However, there is no guarantee that CVR holders will receive any payments.
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) announced a trial-in-progress poster presentation for its product candidate SB 11285 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), scheduled for November 9-14, 2020. SB 11285, an intravenously administered STING agonist, is being evaluated in a Phase 1a/1b clinical trial both as a monotherapy and in combination with Roche’s PD-L1 inhibitor, Tecentriq. The poster will provide updates on the trial's progress, available on the SITC website on November 11, 2020.
Spring Bank Pharmaceuticals (Nasdaq: SBPH) announced a strategic combination with F-star Therapeutics aimed at advancing a pipeline of immuno-oncology programs. This follows the termination of its Phase 2b hepatitis B program. The combination, expected to close in Q4 2020, will enhance clinical capabilities. SBPH is also progressing its IV SB 11285 trial, with abstracts accepted for presentation at major oncology conferences. As of June 30, 2020, the company reported $23.5 million in cash, a net loss of $6.5 million, with significantly lower operating expenses compared to the previous year.
Spring Bank Pharmaceuticals (SBPH) has announced a definitive share exchange agreement to acquire F-star Therapeutics, creating a combined entity that will focus on immuno-oncology. The new company will operate under the name F-star Therapeutics and advance multiple clinical-stage programs. Prior to closing, the combined company expects to have at least $40 million in cash. Spring Bank stockholders will receive contingent value rights linked to F-star’s STING agonist and antagonist programs, potentially adding value. A conference call is scheduled for July 30, 2020.
Spring Bank Pharmaceuticals (Nasdaq: SBPH) announced progress in its Phase 1a/1b clinical trial of SB 11285, an intravenously-administered STING agonist for advanced solid tumors. The Safety Review Committee has recommended dose escalation to monotherapy level 3 and initiation of combination dosing with Roche’s atezolizumab (Tecentriq). No dose limiting toxicities or serious adverse events have been reported. The trial continues amid the COVID-19 pandemic, maintaining its schedule. Additionally, a clinical poster on the trial was presented at the ASCO Virtual Annual Meeting.
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) announced its participation in the Jefferies Virtual Global Healthcare Conference from June 2-4, 2020. Martin Driscoll, the President and CEO, will present on June 2, 2020, from 4:00 PM to 4:25 PM EDT. The presentation will be accessible on the company's website. Spring Bank focuses on developing novel therapeutics for viral infections, inflammatory diseases, and cancers, with its lead candidate SB 11285 aimed at treating selected cancers. For more details, visit www.springbankpharm.com.
Spring Bank Pharmaceuticals (SBPH) reported its Q1 2020 financial results, highlighting advancements in its IV SB 11285 clinical trial, which is on track to include Roche's Tecentriq later this summer. Despite COVID-19 challenges, patient dosing continues in the Phase 1a/1b trial. The company's cash position is $47.5 million, allowing operations through Q1 2022. Operating expenses totaled $8.2 million, with a net loss of $8.2 million for Q1 2020, compared to $5.2 million in Q1 2019. Spring Bank also aims to advance its STING agonist program and explore RIG-I agonists for COVID-19 treatments.
